Bragar Eagel & Squire, P.C. is Investigating Tencent Music Leisure Group on Behalf of Tencent Stockholders and Encourages Buyers to Contact the Agency


Wells Fargo: 2 Strong Stocks With Upward Potential Above 70%

Wells Fargo analysts have scrutinized the market, or specifically the winners and losers of current market conditions. In a recent release, senior equity analyst Chris Harvey writes, “The risk and outperformance of small caps have made this stock market a haven for stock pickers.” Obviously, Harvey sees that small-cap stocks are doing well right now and are doing well for investors numerous options are available to choose from. While small caps are generally a riskier investment, one distinct advantage over bigger names is the potential for higher returns. This is where the risk / reward paradigm comes into play. Following Harvey’s tip, the company has made a number of recommendations and found small-cap stocks on the cusp of growth that promise a return of 70% or more for the coming year. We ran two of them through the TipRanks database to see what other Wall Street analysts were up to. Ping Identity Holding (PING) Based on the technology industry, Wells Fargo’s first pick is Ping Identity Holding Corp, which specializes in identity management. The company offers a range of products that customers can use to control login and access to networks and databases. While Ping Identity has been in business for nearly 20 years, it has only been a public company for a year and a half. In the company’s most recent quarterly report for the fourth quarter of 2010, Ping reported mixed results, and immediately posted a 20% decline in price. The EPS was a net loss of 4 cents per share. Revenue was down 7% year-over-year to $ 63.2 million, but increased 5.5% sequentially, marking the second highest quarterly revenue the company has had since going public. For the full year, total revenue was $ 243.6 million, driven by a 15% increase in annual recurring revenue (ARR) year over year, which hit $ 259.1 million. The company saw a 34% increase in customers with an ARR of more than $ 1 million, a solid win on one key metric. Wells Fargo analyst Philip Winslow was particularly impressed with the ARR gain. “Ping reported solid fourth quarter results, with ARR exceeding expectations. The 15% year-over-year ARR growth was above consensus estimates of $ 256.1 million due to continued adoption of SaaS solutions, which accelerated more than expected and accounted for + 15% of total ARR, ” wrote the 5-star analyst. Winslow added, “The company is seeing continued signs of pent-up demand as customers phased out their purchases as projects previously suspended from COVID budget pressures emerge in the pipeline and companies modernize legacy systems whose flaws are exposed been the past year. “To this end, Winslow rates PING as overweight (i.e. buy) and has a target price of $ 40, indicating upside potential of 76% over the next 12 months. (To see Winslow’s track record, click here.) Winslow is not an outlier in his bullish stance, but there is some divide on Wall Street over ping. The analysts’ consensus view is a moderate buy based on a dozen ratings that consisted of 7 buys and 5 holds The shares are priced at $ 22.59 and their average target price of $ 33.71 indicates a year-long share Upward movement of 49%. (See PING stock analysis on TipRanks.) Sangamo Therapeutics (SGMO) Let’s shift gears and take a look at the life science sector. Sangamo is a biotechnology company focused on developing genomic therapies to treat genetic diseases. The company’s pipeline includes 17 different programs at various stages of development that target a range of diseases, including IBD, beta thalassemia, sickle cell disease and hemophilia A. Back in December, the company reported an update on its ongoing collaboration with Pfizer on Giroctocogene fitelparvovec. This is a gene therapy product that is being developed to treat haemophilia A. Follow-up data from the Phase 1/2 Alta study indicated that the drug was well tolerated and safe in the small cohort of patients tested. Giroctocogene fitelparvovec is now starting the patient dosage phase of the phase 3 AFFINE study. In February, Sangamo reported that it had entered into a global partnership with Biogen to develop and commercialize new therapies for gene regulation. The therapies under consideration target Alzheimer’s, Parkinson’s and other neurological diseases. The bulls include Wells Fargo analyst Yanan Zhu, who wrote of the bigger picture: “Overall, we continue to see significant upside in the company’s genomic drug pipeline programs and platforms, particularly the regulatory T (Treg) cell therapy platform may target a wide range of autoimmune diseases and the ZFP-TF gene regulatory platform, which may target certain difficult-to-target neurological indications… ”In light of these comments, Zhu reiterates the company’s overweight (i.e. buy) rating on the stock and set up target price $ 29, suggesting a robust upward move of 158%. (To see Zhu’s track record, click here.) Overall, SGMO has shown optimism and caution about the consensus view among sell-side analysts. Out of 5 analysts surveyed over the past 3 months, 2 are bullish about the stock while 3 continue to fail. The bulls have the edge, however, as the average price target is $ 19.40 and indicates a 72% uptrend. (See SGMO stock analysis on TipRanks.) To find great ideas for trading stocks at attractive valuations, visit TipRanks’ Best Stocks to Buy, ‘a newly launched tool that brings together all of TipRanks’ stock insights. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.

World traders proceed to pour cash into fairness funds, shrugging off inflation fears

(Reuters) – Global investors continued to put money into equity funds in hopes of a global economic recovery and vaccine optimism, and to allay concerns about inflation levels.

FILE PHOTO: An almost empty trading floor can be seen on the New York Stock Exchange (NYSE) in New York, USA on May 22, 2020. REUTERS / Brendan McDermid

Equity fund inflows doubled from last week to $ 20.4 billion in the week ended March 10, data from Refinitiv Lipper showed.

However, investors sold global bond funds $ 2.7 billion net as US Treasury yields hit a 1-year high this week.

Chart: Fund flows into global reverse convertibles and money markets –

Meanwhile, investors have also put $ 28.7 billion worth of money into safer money market funds, the data showed.

In equity funds, technology funds saw an outflow for the first time in a year due to rising bond yields. Higher returns lower the present value of future cash flows from growth stocks.

On the flip side, the financial sector saw an inflow of $ 3.14 billion, the largest in eight weeks when investors poured money into cyclical stocks amid growing optimism about a global economic recovery.

Chart: Global bond outflows for the week ending March 10 –

Other sectors that rise and fall along with business cycles, such as industrial, energy and mining companies, also saw inflows this week.

Among the commodity funds, precious metals funds posted net sales of $ 1.74 billion for the fifth consecutive year. This signals that investors are looking to safer assets like gold and are willing to take higher risks.

Graphic: Global Fund Flows into Equity Sectors –

An analysis of 23,755 emerging market funds found that equity funds generated $ 2.3 billion in inflows. Annuity funds recorded net sales of $ 3.4 billion, the largest outflow for the latter in about a year.

Chart: Fund flows into EM stocks and bonds –

Reporting by Gaurav Dogra and Patturaja Murugaboopathy in Bengaluru; Adaptation by Larry King

Stanley Druckenmiller, Invoice Ackman amongst early Coupang traders

Stanley Printmiller (L) and Bill Ackman


South Korean e-commerce giant Coupang, which rose sharply on its Wall Street debut, received early support from some high profile investors: Stanley Printmiller and Bill Ackman.

Coupang, called Amazon of South Korea, nearly doubling from its $ 35 per share price shortly after it opened on Thursday lunchtime on the New York Stock Exchange.

The stock later reduced those gains, closing nearly 41% at $ 49.25 per share, giving Coupang a market cap of $ 84.5 billion.

Printmiller, the billionaire CEO of the Duquesne Family Office, was a long-time pre-IPO investor in the Seoul-based company. Kevin Warsh, an advisor to Druckermiller, told CNBC’s Becky Quick. Warsh, a former Federal Reserve Governor, joined the board of directors of Coupang in 2019. Warsh owns a total of 280,662 shares of Coupang, according to a Filing with the Securities and Exchange Commission.

Ackman, the billionaire who runs Pershing Square Capital Management hedge fund, personally invested in Coupang, a source close to the situation, CNBC said. It is unclear when this investment was made. But a Reuters report in 2014 mentions Ackman as an investor.

Coupang raised $ 4.6 billion in its initial public offering, the largest so far in the US this year. The company sold 130 million shares on Wednesday night at $ 35 each, above its target range of $ 32-34.

The company was founded in 2010 by Bom Kim who continues to serve as CEO. Other investors are Masayoshi Son’s SoftBank group.

“When we talk about Coupang for what it is, it’s Amazon, but it’s Amazon with one UPS attached to it with With the Dash, with Instacart, with a little shot Netflix and it’s all integrated on this technology platform with an extreme level of customer focus, “he said Lydia Jett, Investment partner at SoftBank Vision Fund and member of the Coupang Board of Directors since 2018.

SoftBank’s Vision Fund owns around a third of Coupang invested billions of dollars into the company. In an interview on CNBCs “Squawk Alley” Jett said it didn’t take long to realize Kim is a top notch founder who deserves support.

“When I met Bom and spent three days with him in Seoul, I was overwhelmed by his company’s customer understanding and focus, the innovation that was taking place,” said Jett. “I knew that this company was doing something radically different from its competition and that customers were responding,” she added. “You can see that in the company’s numbers.”

Coupang’s total sales in 2020 were $ 12 billion, up nearly 91% year over year. In 2020, the company posted an operating loss of $ 527.7 million – an 18% decrease from 2019 and a decrease of nearly 50% from 2018.

The company was ranked # 2 on the CNBC Disruptor 50 list last year.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Invitations GameStop Corp. (GME), AMC Leisure Holdings, Inc. (AMC) and BlackBerry Ltd. (BB) Buyers to Contact its Attorneys, Agency Investigating On-line Brokerages’ Market Manipulation Scheme


Those 2 penny stocks could rally as much as $ 11, analysts say

At its FOMC meeting in January, the Federal Reserve held rates stable – they are currently near their lows, and unsurprisingly, the Fed is holding them there. Fed chairman Jerome Powell may have fed some market pessimism when speaking after the meeting, pointing out that unemployment has risen in recent months. For market watchers seeking support, there is consolation in the Fed’s monetary policy. The central bank has pledged to buy $ 80 billion worth of Treasury bills every month and has put a rate hike on hold until 2023. At least one top strategist sees the current market environment in terms of opportunities. JPMorgan strategist Marko Kolanovic takes an optimistic stance and writes: “We assume that the global COVID pandemic will decline rapidly in the coming weeks. In fact, the pace of decline in new cases in the past two weeks is the fastest ever in the US and worldwide. Central banks should remain accommodative amid rising unemployment and over a decade of low inflation that is below their targets – term turmoil like this week offers an opportunity to switch from bonds to stocks. “With that outlook in mind, we set out to find exciting opportunities that won’t break the bank, namely penny stocks. Priced at $ 5 or less, these stocks offer investors the highest growth potential available in the market. Again, there is a risk, as the “pennies” are often cheap for a reason. Careful examination is therefore essential. Using TipRanks’ database, we identified two penny stocks that received a consensus rating of “Strong Buy” from the analyst community. Not to mention, every company has huge upside potential as some analysts see it spike to $ 11. BioLineRx, Ltd. (BLRX) We’re starting BioLineRx, a clinical-stage biopharmaceutical company focused on developing new cancer treatments. Oncology is an important area for state-of-the-art biopharmaceuticals. Cancer is often fatal and often resistant to topical treatments – and these treatments themselves often cause severe side effects in patients. BioLineRx has an active pipeline of drug candidates. The most advanced, however, is motixafortid, a synthetic peptide that has completed patient enrollment in a phase 3 study to mobilize stem cells for autologous bone marrow transplantation. The drug is being studied for effectiveness in promoting bone marrow harvesting prior to cancer treatment. The results of a pre-planned interim analysis showed “statistically significant evidence for motixafortid treatment at the primary endpoint” so significant that enrollment was completed early with 122 patients instead of 177. Mobilizing stem cells using Motixafortid is believed to be the company’s most efficient route to registering the new drug for regulatory approval. Given the potential of Motixafortide and its share price of $ 2.40, some analysts believe now is the time to pull the trigger. Mark Breidenbach, 5-star analyst, reported on BLRX for Oppenheimer: “Our thesis continues to focus on motixafortid in the mobilization of stem cells, and we see a separation between the company’s market capitalization and the market opportunity of Motixafortid as a stem cell mobilizer. The key GENESIS secondary endpoints are expected by mid-2021 and we see little risk for this data … “The analyst added,” We believe the results of the Phase 3 GENESIS trial will prompt the majority of transplant doctors might choose to combine BL-8040 with G-CSF instead of Mozobil if the drug is approved. In addition to our work, BL-8040 contains for use in other auto-HSCTs, allo-HSCTs, AML, and solid tumors. The company has a catalyst-rich, deep oncology pipeline that has attracted collaborations with Novartis, Merck and Genentech. “With all of this in mind, Breidenbach rates BLRX as a buy, and its target price of $ 11 points to an uptrend of a whopping 358% for the coming year. (To see Breidenbach’s track record, click here.) The rest of the street seems to reflect Breidenbach’s bullish sentiment. With 3 buys and no holds or sells, the consensus is unanimous: BLRX is a strong buy. On top of the good news, the upside is ~ 428% based on the average price target of $ 12.67. (See BLRX stock analysis on TipRanks) Kindred Biosciences (KIN) While most biotech companies focus on human drugs, we’re not the only market. Kindred Biosciences is a biopharmaceutical company in the veterinary marketplace developing biological medicines to improve the lives of our pets and work animals. The company describes its mission as'[bringing] Pet the same safe and effective medications that human family members enjoy. Parvovirus (CPV) is a highly infectious and fatal viral disease that affects dogs. While vaccines are available, untreated cases can have a mortality rate of over 91%. Kindred’s lead drug in the pipeline, KIND-030, is currently in development for the treatment of this disease. The drug candidate is currently pursuing two paths in the development process – one for the treatment of established infections and one for the prophylactic preventive treatment of CPV. The prophylactic study showed positive results, with all dogs treated avoiding infection while all dogs in the placebo group developed parvovirus disease. KIND-030 also showed a mortality benefit when given to treat infections. The drug candidate is in the crucial study phase of development, the last before possible approval. Last month, Kindred announced it had entered into an agreement with Elanco Animal Health, a major veterinary drug company, to manufacture KIND-030. Cantor analyst Brandon Folkes sees a lot of potential in Kindred, especially in the company’s agreement with Elanco. “A partnership with a leading animal health company, in this case Elanco, is exactly what the company needs from our point of view. This confirms, in our view, KIN’s new strategic approach as a drug developer to find larger trading partners. We believe today’s deal should show investors that Kindred’s pipeline continues to have significant value that could be realized in the next 12 to 18 months, ”said Folkes. Kindred is also conducting studies with tirnovetmab, or KIND-016, an antibody directed against IL31, for the treatment of atopic dermatitis in dogs. The pivotal efficacy study of this drug began in the final quarter of 2020. There is a potentially huge market for successful dermatitis treatment in dogs. Over the past six years, there has been a 47% increase in veterinary visits for dogs with severely itchy skin and the market is valued at $ 900 million or more. “While 2020 was a tough year for KIN stock, the company continued to take several shots on goal from its diversified pipeline that could reward investors at current levels. With multiple readings in 2021 and once again focusing solely on developing its pipeline, we anticipate that 2021 could be a banner year for KIN should it be able to deliver on the promise of its pipeline and, in particular, its atopic dermatitis portfolio, ” so the analyst summarized. To do this, Folkes gives KIN a price target of $ 11, which means an upside of 139% in 2021 and an overweight (i.e. buy). (To see Folkes’ track record, click here.) Kindred is another company with a unanimous consensus from Strong Buy analysts based on 5 recent Buy ratings. The stock has an average price target of $ 10.25, indicating ~ 124% growth from the current trading price of $ 4.59. (See KIN Stock Analysis on TipRanks.) To find great ideas for trading penny stocks at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that brings together all of the insights into TipRanks stocks. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.

Smaller traders face down hedge funds, as GameStop soars | Leisure

Meanwhile, a cavalry of smaller investors on the Internet have admonished each other to keep the stock’s momentum moving towards the moon. Many pose as the fight of the regular people against hedge funds and big Wall Street firms.

It took only five days for GameStop stock to double after the board restructuring was announced. Last Friday it was up 51%, a bigger gain than big stocks like Apple or Exxon Mobil ever in a day. For GameStop, the 51% move was just the second best day of the month – and the month isn’t over yet.

The meteoric surge caused some short sellers to get out of their bets by buying stocks, and this helped add to the momentum. On Monday, the push and pull was so extreme that trading in GameStop shares was temporarily stopped at least nine times due to volatility.

It closed at $ 76.79 on Monday after fluctuating between $ 65.01 and $ 159.18 earlier in the day.

“This is a real experience for my first month on the stock market. Hold on to infinity, ”one user wrote on a Reddit discussion about GameStop stock. A moment later, another user said, “We’re literally more powerful than the big companies right now.”

The same feeling went well beyond Internet message boards to Wall Street.

“As someone who started trading stocks in college in the late 1990s, I always remembered the small retail groups being crushed by hedge funds and savvy short sellers,” said Edward Moya, senior market analyst at OANDA, in a report. “What happened to GameStop stock is a reminder of how times change.”

Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.